Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Meningococcal Disease Vaccine Global Market Report 2025
Download Free Sample Buy Now
Global Meningococcal Disease Vaccine Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Meningococcal Disease Vaccine Global Market Report 2025

By Vaccine Type (Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, Live Attenuated Vaccines), By Age Group (Infants, Children, Adults, Older Adults), By Indication (Preventive Vaccination, Post-Exposure Prophylaxis, Travel-Related Vaccination, Outbreak Response), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-Users (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Meningococcal Disease Vaccine Market Overview

• Meningococcal Disease Vaccine market size has reached to $2.37 billion in 2024

• Expected to grow to $3.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%

• Growth Driver: Government Immunization Programs Fueling The Growth Of The Market Due To Increasing Access Awareness And Mandates

• Market Trend: Advancements In Meningococcal Disease Vaccine Development And Serogroup Coverage Expansion

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Meningococcal Disease Vaccine Market?

The meningococcal disease vaccine refers to a vaccine that protects against meningococcal disease, a serious bacterial infection caused by the bacterium Neisseria meningitidis. This disease can lead to meningitis (inflammation of the membranes around the brain and spinal cord) and septicemia (blood poisoning), both of which can be life-threatening.

The main types of meningococcal disease vaccines are conjugate vaccines, polysaccharide vaccines, recombinant vaccines, and live attenuated vaccines. Conjugate vaccines enhance immunity by linking bacterial sugars to proteins, offering effective protection against strains A, C, W, and Y, especially for adolescents and high-risk individuals. It is specifically available for various age groups, such as infants, children, adults, and older adults, for several indications, including preventive vaccination, post-exposure prophylaxis, travel-related vaccination, and outbreak response. It is distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and is used by various end-users including hospitals, specialty clinics, home care, and others.

Meningococcal Disease Vaccine Market Size and growth rate 2025 to 2029: Graph

What Is The Meningococcal Disease Vaccine Market Size 2025 And Growth Rate?

The meningococcal disease vaccine market size has grown rapidly in recent years. It will grow from $2.37 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to improving vaccine manufacturing capacity, global health partnerships, inclusion in national immunization schedules, the rise in meningococcal disease cases, and rising efforts by organizations.

What Is The Meningococcal Disease Vaccine Market Growth Forecast?

The meningococcal disease vaccine market size is expected to see rapid growth in the next few years. It will grow to $3.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to growing awareness of preventive healthcare, expanding target age groups, entry of new market players, government and health agency stockpiling for potential outbreaks, and increasing public awareness. Major trends in the forecast period include advancements in vaccine technology, the development of multivalent, conjugate, and protein-based vaccines, global travel and migration trends, growth in research and development for mRNA, and innovations in thermostable formulations.

The forecast of 9.7% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. immunization programs by increasing costs for conjugate meningococcal vaccines and adjuvant components imported from Italy and Brazil, potentially slowing outbreak responses and raising public health expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Meningococcal Disease Vaccine Market Segmented?

1) By Vaccine Type: Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, Live Attenuated Vaccines

2) By Age Group: Infants, Children, Adults, Older Adults

3) By Indication: Preventive Vaccination, Post-Exposure Prophylaxis, Travel-Related Vaccination, Outbreak Response

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Conjugate Vaccines: Monovalent Conjugate Vaccines, Quadrivalent Conjugate Vaccines, Pediatric Conjugate Vaccines, Adolescent Or Adult Conjugate Vaccines

2) By Polysaccharide Vaccines: Bivalent Polysaccharide Vaccines, Trivalent Polysaccharide Vaccines, Quadrivalent Polysaccharide Vaccines, Age-Specific Polysaccharide Formulations

3) By Recombinant Vaccines: Serogroup B Recombinant Protein Vaccines, Multicomponent Recombinant Vaccines, Outer Membrane Vesicle (OMV) Based Recombinant Vaccines

4) By Live Attenuated Vaccines: Experimental Intranasal Live Attenuated Vaccines, Genetically Engineered Attenuated Strain Vaccines, Combined Live Attenuated Vaccines

What Is Driving The Meningococcal Disease Vaccine Market? Government Immunization Programs Fueling The Growth Of The Market Due To Increasing Access Awareness And Mandates

The increasing government immunization programs are expected to propel the growth of the meningococcal disease vaccine market going forward. Government immunization programs are health initiatives that offer free or low-cost vaccines to safeguard communities against infectious diseases. Government immunization programs are growing due to a heightened emphasis on preventing infectious diseases and alleviating healthcare burdens through widespread vaccinations. Government immunization programs drive the growth of meningococcal vaccines by expanding access and increasing vaccination rates while raising awareness and reducing disease incidence. They also create demand by mandating vaccinations and promoting public health. For instance, in April 2024, according to the Pan American Health Organization (PAHO), a US-based specialized agency, the 22nd Vaccination Week in the Americas (VWA), with the theme Engage now to protect your future. GetVax was launched aiming to increase vaccination coverage, especially in underserved areas, by administering over 65 million doses. The initiative focused on combating misinformation and enhancing access to vaccines through community engagement and tailored campaigns. Therefore, the increasing government immunization programs driving the growth of the meningococcal disease vaccine industry.

Who Are The Major Players In The Global Meningococcal Disease Vaccine Market?

Major companies operating in the meningococcal disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, Immunopreparat.

What Are The Key Trends Of The Global Meningococcal Disease Vaccine Market? Advancements In Meningococcal Disease Vaccine Development And Serogroup Coverage Expansion

Major companies operating in the meningococcal disease vaccine market are focused on developing advanced products, such as pentavalent meningococcal vaccines, to expand serogroup coverage, streamline immunization schedules, and improve disease prevention. A pentavalent meningococcal vaccine is an advanced immunization solution that targets five major serogroups of Neisseria meningitidis in a single dose, reducing the need for multiple separate vaccinations and improving compliance. For instance, in October 2023, Pfizer Inc., a US-based biopharmaceutical company, announced the Food and Drug Administration (FDA) approval for PENBRAYA, the first and only vaccine for the prevention of meningococcal disease in individuals aged 10 to 25 years. This innovative vaccine combines components from two existing meningococcal vaccines, Trumenba and Nimenrix, to protect against the five most common serogroups (A, B, C, W, and Y) of Neisseria meningitidis that cause the majority of invasive meningococcal disease (IMD) globally. PENBRAYA represents a significant advancement in meningococcal disease prevention, offering the broadest serogroup coverage of any meningococcal vaccine available in the U.S. and potentially simplifying the vaccination schedule by reducing the total number of doses required for full protection.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Meningococcal Disease Vaccine Market? Biovac Partnered With Eubiologics To Boost Africa’s Vaccine Self-Reliance With Local Meningitis Vaccine Production

In September 2023, Biovac, a South Africa-based biopharmaceutical company, partnered with EuBiologics Co. Ltd. to empower Africa through local vaccine innovation and self-reliance. The partnership aims to transfer technology and locally manufacture meningococcal meningitis pentavalent conjugate vaccine in Africa, addressing critical health needs in the meningitis belt and advancing the continent’s vaccine self-sufficiency. EuBiologics Co., Ltd. is a South Korea-based manufacturer of pentavalent meningococcal conjugate vaccine.

What Is The Regional Outlook For The Global Meningococcal Disease Vaccine Market?

North America was the largest region in the meningococcal disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Meningococcal Disease Vaccine Market?

The meningococcal disease vaccine market consists of sales of protein-based vaccines, outer membrane vesicle (OMV) vaccines, and multicomponent vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Meningococcal Disease Vaccine Industry?

The meningococcal disease vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal disease vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Meningococcal Disease Vaccine Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $2.59 billion
Revenue Forecast In 2034 $3.75 billion
Growth Rate CAGR of 9.7% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The meningococcal disease vaccine market covered in this report is segmented –
1) By Vaccine Type: Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, Live Attenuated Vaccines
2) By Age Group: Infants, Children, Adults, Older Adults
3) By Indication: Preventive Vaccination, Post-Exposure Prophylaxis, Travel-Related Vaccination, Outbreak Response
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments:
1) By Conjugate Vaccines: Monovalent Conjugate Vaccines, Quadrivalent Conjugate Vaccines, Pediatric Conjugate Vaccines, Adolescent Or Adult Conjugate Vaccines
2) By Polysaccharide Vaccines: Bivalent Polysaccharide Vaccines, Trivalent Polysaccharide Vaccines, Quadrivalent Polysaccharide Vaccines, Age-Specific Polysaccharide Formulations
3) By Recombinant Vaccines: Serogroup B Recombinant Protein Vaccines, Multicomponent Recombinant Vaccines, Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
4) By Live Attenuated Vaccines: Experimental Intranasal Live Attenuated Vaccines, Genetically Engineered Attenuated Strain Vaccines, Combined Live Attenuated Vaccines
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, Immunopreparat.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Meningococcal Disease Vaccine Market Characteristics

3. Meningococcal Disease Vaccine Market Trends And Strategies

4. Meningococcal Disease Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Meningococcal Disease Vaccine Growth Analysis And Strategic Analysis Framework

5.1. Global Meningococcal Disease Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Meningococcal Disease Vaccine Market Growth Rate Analysis

5.4. Global Meningococcal Disease Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Meningococcal Disease Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Meningococcal Disease Vaccine Total Addressable Market (TAM)

6. Meningococcal Disease Vaccine Market Segmentation

6.1. Global Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Conjugate Vaccines

Polysaccharide Vaccines

Recombinant Vaccines

Live Attenuated Vaccines

6.2. Global Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Infants

Children

Adults

Older Adults

6.3. Global Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Preventive Vaccination

Post-Exposure Prophylaxis

Travel-Related Vaccination

Outbreak Response

6.4. Global Meningococcal Disease Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Other Distribution Channels

6.5. Global Meningococcal Disease Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End-Users

6.6. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monovalent Conjugate Vaccines

Quadrivalent Conjugate Vaccines

Pediatric Conjugate Vaccines

Adolescent Or Adult Conjugate Vaccines

6.7. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Polysaccharide Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Bivalent Polysaccharide Vaccines

Trivalent Polysaccharide Vaccines

Quadrivalent Polysaccharide Vaccines

Age-Specific Polysaccharide Formulations

6.8. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Serogroup B Recombinant Protein Vaccines

Multicomponent Recombinant Vaccines

Outer Membrane Vesicle (OMV) Based Recombinant Vaccines

6.9. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Experimental Intranasal Live Attenuated Vaccines

Genetically Engineered Attenuated Strain Vaccines

Combined Live Attenuated Vaccines

7. Meningococcal Disease Vaccine Market Regional And Country Analysis

7.1. Global Meningococcal Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Meningococcal Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Meningococcal Disease Vaccine Market

8.1. Asia-Pacific Meningococcal Disease Vaccine Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Meningococcal Disease Vaccine Market

9.1. China Meningococcal Disease Vaccine Market Overview

9.2. China Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Meningococcal Disease Vaccine Market

10.1. India Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Meningococcal Disease Vaccine Market

11.1. Japan Meningococcal Disease Vaccine Market Overview

11.2. Japan Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Meningococcal Disease Vaccine Market

12.1. Australia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Meningococcal Disease Vaccine Market

13.1. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Meningococcal Disease Vaccine Market

14.1. South Korea Meningococcal Disease Vaccine Market Overview

14.2. South Korea Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Meningococcal Disease Vaccine Market

15.1. Western Europe Meningococcal Disease Vaccine Market Overview

15.2. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Meningococcal Disease Vaccine Market

16.1. UK Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Meningococcal Disease Vaccine Market

17.1. Germany Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Meningococcal Disease Vaccine Market

18.1. France Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Meningococcal Disease Vaccine Market

19.1. Italy Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Meningococcal Disease Vaccine Market

20.1. Spain Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Meningococcal Disease Vaccine Market

21.1. Eastern Europe Meningococcal Disease Vaccine Market Overview

21.2. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Meningococcal Disease Vaccine Market

22.1. Russia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Meningococcal Disease Vaccine Market

23.1. North America Meningococcal Disease Vaccine Market Overview

23.2. North America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Meningococcal Disease Vaccine Market

24.1. USA Meningococcal Disease Vaccine Market Overview

24.2. USA Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Meningococcal Disease Vaccine Market

25.1. Canada Meningococcal Disease Vaccine Market Overview

25.2. Canada Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Meningococcal Disease Vaccine Market

26.1. South America Meningococcal Disease Vaccine Market Overview

26.2. South America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Meningococcal Disease Vaccine Market

27.1. Brazil Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Meningococcal Disease Vaccine Market

28.1. Middle East Meningococcal Disease Vaccine Market Overview

28.2. Middle East Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Meningococcal Disease Vaccine Market

29.1. Africa Meningococcal Disease Vaccine Market Overview

29.2. Africa Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Meningococcal Disease Vaccine Market Competitive Landscape And Company Profiles

30.1. Meningococcal Disease Vaccine Market Competitive Landscape

30.2. Meningococcal Disease Vaccine Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Meningococcal Disease Vaccine Market Other Major And Innovative Companies

31.1. Hualan Biological Engineering Inc.

31.2. Beijing Tiantan Biological Products Corporation Limited

31.3. Serum Institute of India Pvt. Ltd.

31.4. Walvax Biotechnology Co. Ltd.

31.5. Incepta Pharmaceuticals Ltd.

31.6. CanSino Biologics Inc.

31.7. EuBiologics Co. Ltd.

31.8. Biovac Institute

31.9. Shantha Biotech

31.10. Bio-Manguinhos

31.11. Biomed Pvt. Ltd.

31.12. Chengdu Kanghua Biological Products Co. Ltd.

31.13. Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.

31.14. Finlay Institute of Vaccines

31.15. Immunopreparat

32. Global Meningococcal Disease Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Meningococcal Disease Vaccine Market

34. Recent Developments In The Meningococcal Disease Vaccine Market

35. Meningococcal Disease Vaccine Market High Potential Countries, Segments and Strategies

35.1 Meningococcal Disease Vaccine Market In 2029 - Countries Offering Most New Opportunities

35.2 Meningococcal Disease Vaccine Market In 2029 - Segments Offering Most New Opportunities

35.3 Meningococcal Disease Vaccine Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Meningococcal Disease Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Meningococcal Disease Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Polysaccharide Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Meningococcal Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Meningococcal Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Pfizer Inc. Financial Performance
  • Table 81: Merck & Co. Inc. Financial Performance
  • Table 82: Sanofi SA Financial Performance
  • Table 83: Novartis AG Financial Performance
  • Table 84: GlaxoSmithKline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Meningococcal Disease Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Meningococcal Disease Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Polysaccharide Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Meningococcal Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Meningococcal Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Pfizer Inc. Financial Performance
  • Figure 81: Merck & Co. Inc. Financial Performance
  • Figure 82: Sanofi SA Financial Performance
  • Figure 83: Novartis AG Financial Performance
  • Figure 84: GlaxoSmithKline plc Financial Performance

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Read More About A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Vaccines Global Market Report 2022 – By Type (Anti-Infective Vaccines, Autoimmunity, Others (Cancer And Others)), By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant...

View Report

Preventive Vaccines Global Market Report 2025 - By Type (Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines), By Disease Ty...

View Report

Respiratory Disease Vaccine Global Market Report 2025 – By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), By Infection (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections),...

View Report

Protective Relays And Circuit Breakers Global Market Report 2025 – By Type (Protective Relays, Circuit Breakers), By Voltage Rating (Low Voltage (Up To 1kV), Medium Voltage (1kV – 69kV), High Voltage (Above 69kV)), By Ap...

View Report

Adult Vaccines Global Market Report 2025 – By Vaccine Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vac...

View Report

Meningococcal Vaccines Global Market Report 2025 – By Vaccine Type (Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine), By Serotype (Men Acwy, Men B/Bc, Men C), By Age Group (Infants, Children, Adolesc...

View Report

Meningococcal Disease Vaccine Global Market Report 2025 – By Vaccine Type (Conjugate Vaccines, Polysaccharide Vaccines, Recombinant Vaccines, Live Attenuated Vaccines), By Age Group (Infants, Children, Adults, Older Adul...

View Report

Pneumococcal Vaccine Global Market Report 2025 – By Product Type (Prevnar 13, Synflorix, Pneumovax23, Other Products), By Route of Administration (Intravenous, Intramuscular, Subcutaneous), By Distribution Channel (Pharm...

View Report

Frequently Asked Questions

The meningococcal disease vaccine refers to a vaccine that protects against meningococcal disease, a serious bacterial infection caused by the bacterium Neisseria meningitidis. This disease can lead to meningitis (inflammation of the membranes around the brain and spinal cord) and septicemia (blood poisoning), both of which can be life-threatening. For further insights on this market, request a sample here

The market major growth driver - Government Immunization Programs Fueling The Growth Of The Market Due To Increasing Access Awareness And Mandates. For further insights on this market, request a sample here

The meningococcal disease vaccine market size has grown strongly in recent years. It will grow from $2.37 billion in 2024 to $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to improving vaccine manufacturing capacity, global health partnerships, inclusion in national immunization schedules, the rise in meningococcal disease cases, and rising efforts by organizations. The meningococcal disease vaccine market size is expected to see strong growth in the next few years. It will grow to " $3.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to growing awareness of preventive healthcare, expanding target age groups, entry of new market players, government and health agency stockpiling for potential outbreaks, and increasing public awareness. Major trends in the forecast period include advancements in vaccine technology, the development of multivalent, conjugate, and protein-based vaccines, global travel and migration trends, growth in research and development for mRNA, and innovations in thermostable formulations. For further insights on this market, request a sample here

The meningococcal disease vaccinemarket covered in this report is segmented –
1) By Vaccine Type: Conjugate Vaccines; Polysaccharide Vaccines; Recombinant Vaccines; Live Attenuated Vaccines
2) By Age Group: Infants; Children; Adults; Older Adults
3) By Indication: Preventive Vaccination; Post-Exposure Prophylaxis; Travel-Related Vaccination; Outbreak Response
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users Subsegments:
1) By Conjugate Vaccines: Monovalent Conjugate Vaccines; Quadrivalent Conjugate Vaccines; Pediatric Conjugate Vaccines; Adolescent Or Adult Conjugate Vaccines
2) By Polysaccharide Vaccines: Bivalent Polysaccharide Vaccines; Trivalent Polysaccharide Vaccines; Quadrivalent Polysaccharide Vaccines; Age-Specific Polysaccharide Formulations
3) By Recombinant Vaccines: Serogroup B Recombinant Protein Vaccines; Multicomponent Recombinant Vaccines; Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
4) By Live Attenuated Vaccines: Experimental Intranasal Live Attenuated Vaccines; Genetically Engineered Attenuated Strain Vaccines; Combined Live Attenuated Vaccines For further insights on this market, request a sample here

North America was the largest region in the meningococcal disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the meningococcal disease vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the meningococcal disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, Immunopreparat. . For further insights on this market, request a sample here.

Major trends in this market include Advancements In Meningococcal Disease Vaccine Development And Serogroup Coverage Expansion. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Meningococcal Disease Vaccine Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon